STOCKHOLM, April 27, 2021 /PRNewswire/ -- Calliditas
Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) announces
today that the Board has decided that the interim report for the
first quarter 2021 will be published on May
18, 2021. The previously planned date for publication was
May 13, 2021, which is the Ascension
Day.
The information was submitted for publication at 14:30 CET on April 27,
2021, by the below contact person.
For further information, please contact:
Marie Galay, IR Manager,
Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
About Calliditas
Calliditas Therapeutics is a biopharma company based in
Stockholm, Sweden focused on
identifying, developing and commercializing novel treatments in
orphan indications, with an initial focus on renal and hepatic
diseases with significant unmet medical needs. Calliditas' lead
product candidate, Nefecon, is a proprietary, novel oral
formulation of budesonide, an established, highly potent local
immunosuppressant, for the treatment of the autoimmune renal
disease IgA nephropathy, or IgAN, for which there is a high unmet
medical need and there are no approved treatments. Calliditas is
running a global Phase 3 study within IgAN and, if approved, aims
to commercialize Nefecon in the United
States. Calliditas is listed on Nasdaq Stockholm (ticker:
CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit
www.calliditas.com for further information.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/change-in-financial-calendar,c3334531
The following files are available for download:
https://mb.cision.com/Main/16574/3334531/1408163.pdf
|
Change in financial
calendar EN
|
View original
content:http://www.prnewswire.com/news-releases/calliditas-therapeutics-ab-change-in-financial-calendar-301277946.html
SOURCE Calliditas Therapeutics